MDNA55

Property	Information
Drug Name	MDNA55
FDA Approval	No
Used for	Recurrent malignant gliomas
Clinical Trial Phase	Early phase trials
Clinical Trial Explanation	Not specified
Common Side Effects	Not specified in the provided text
OS without	Not specified
OS with	Not specified in the provided text
PFS without	Not specified
PFS with	Not specified in the provided text
Usefulness Rating	3
Usefulness Explanation	Not specified
Toxicity Level	2.5
Toxicity Explanation	The treatment, MDNA55, is in its early phase of trials, meaning that its potential side effects are still being evaluated. Currently, it's not fully approved by the FDA and exact toxicity is not specified. However, MDNA55 is designed to target cells common in tumor tissue, creating a high potential for effectiveness with fewer harmful effects on healthy tissue. It has shown significant positive response rates, suggesting a manageable toxicity profile. Nevertheless, every treatment carries some risk, and potential side effects might still be discovered. The toxicity rating of 2.5 out of 5 indicates a moderate risk of toxic side effects at this point in time.

Notes: MDNA55, a fusion of IL-4 and Pseudomonas exotoxin A, targets cells with high IL-4R expression, common in tumor tissue. Preliminary data shows significant efficacy with a 56% response rate and a 20% complete response rate in recurrent glioblastoma patients treated with a single infusion, highlighting potential as a highly effective treatment.

From Ben Williams Book: Not specified

Loading comments...